ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by StockNews.com to Sell

StockNews.com lowered shares of ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) from a hold rating to a sell rating in a report released on Wednesday morning.

Other equities research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, March 14th. Raymond James decreased their price target on shares of ANI Pharmaceuticals from $65.00 to $47.00 and set an outperform rating for the company in a research note on Wednesday, March 16th. Cantor Fitzgerald restated a neutral rating on shares of ANI Pharmaceuticals in a research note on Wednesday, March 16th. Finally, TheStreet lowered shares of ANI Pharmaceuticals from a c- rating to a d+ rating in a research note on Wednesday, March 30th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals has an average rating of Hold and a consensus price target of $56.67.

NASDAQ:ANIP opened at $30.27 on Wednesday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.74 and a current ratio of 3.68. The firm has a market cap of $522.82 million, a price-to-earnings ratio of -9.31 and a beta of 1.18. ANI Pharmaceuticals has a 52 week low of $24.41 and a 52 week high of $60.23. The firm has a 50-day moving average price of $32.06 and a two-hundred day moving average price of $39.19.

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) last posted its quarterly earnings data on Tuesday, March 15th. The specialty pharmaceutical company reported $0.38 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.31). The firm had revenue of $60.93 million during the quarter, compared to analysts’ expectations of $58.25 million. ANI Pharmaceuticals had a negative net margin of 19.71% and a positive return on equity of 14.10%. During the same quarter last year, the business posted $0.65 EPS. As a group, sell-side analysts forecast that ANI Pharmaceuticals will post 0.58 earnings per share for the current year.

In other news, Director Patrick D. Walsh purchased 5,000 shares of the business’s stock in a transaction on Monday, March 21st. The stock was purchased at an average cost of $27.76 per share, with a total value of $138,800.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Nikhil Lalwani purchased 7,224 shares of the business’s stock in a transaction on Monday, March 21st. The stock was purchased at an average cost of $27.69 per share, with a total value of $200,032.56. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 17,224 shares of company stock valued at $477,083. 27.20% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in ANIP. Comerica Bank lifted its holdings in shares of ANI Pharmaceuticals by 31.1% during the 1st quarter. Comerica Bank now owns 11,195 shares of the specialty pharmaceutical company’s stock worth $367,000 after acquiring an additional 2,655 shares during the last quarter. Thompson Siegel & Walmsley LLC lifted its holdings in shares of ANI Pharmaceuticals by 51.7% during the 1st quarter. Thompson Siegel & Walmsley LLC now owns 424,087 shares of the specialty pharmaceutical company’s stock worth $11,921,000 after acquiring an additional 144,533 shares during the last quarter. Collective Family Office LLC lifted its holdings in shares of ANI Pharmaceuticals by 57.4% during the 1st quarter. Collective Family Office LLC now owns 8,225 shares of the specialty pharmaceutical company’s stock worth $231,000 after acquiring an additional 3,000 shares during the last quarter. Louisiana State Employees Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 19.2% during the 1st quarter. Louisiana State Employees Retirement System now owns 6,200 shares of the specialty pharmaceutical company’s stock worth $203,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Defender Capital LLC. lifted its holdings in shares of ANI Pharmaceuticals by 26.3% during the 1st quarter. Defender Capital LLC. now owns 24,000 shares of the specialty pharmaceutical company’s stock worth $675,000 after acquiring an additional 5,000 shares during the last quarter. 53.51% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile (Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.

Read More

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.